CGCN GROUP, LLC

Lobbying for VERTEX PHARMACEUTICALS INCORPORATED · Biopharmaceutical Company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Massachusetts · House · Senate · $80,000.00 income · posted Jan 20, 2026

Bills named in this filing 2

Lobbying activity 2

Health Issues

Access to innovative non-opioid medicines.

Medicare/Medicaid

Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.